The FDA and the PMTA Process: How Pre-Market Review Reshaped the Vaping Industry

In September 2020, the FDA's deadline for e-cigarette manufacturers to submit Premarket Tobacco Product Applications (PMTAs) arrived, and with it, the most significant regulatory transformation of the U.S. vaping market since the industry's inception. The PMTA process required manufacturers to demonstrate that their products were 'appropriate for the protection of public health'—a standard that required extensive scientific evidence on product chemistry, toxicology, and population health effects. The process was designed to weed out dangerous products, prevent youth marketing, and ensure that the vaping market served public health rather than undermining it. Five years and several million pages of applications later, the PMTA process has achieved some of these goals—and produced outcomes that the FDA's architects did not anticipate.

The scale of the PMTA process was staggering from the start. The FDA received applications for over 6.5 million products—a number that reflected the extraordinary diversity of the pre-PMTA vaping market, with thousands of manufacturers producing tens of thousands of distinct e-liquid flavors, nicotine strengths, and device configurations. The agency's capacity to review these applications—even with the substantial user fees collected from manufacturers—was orders of magnitude smaller than the volume of submissions. The result was a review process that has been slow, selective, and focused on the largest manufacturers and the most popular products. The FDA has authorized a handful of products (primarily tobacco-flavored e-liquids from major manufacturers) and issued marketing denial orders for hundreds of thousands of others—predominantly flavored products from smaller companies. The authorization decisions have reshaped the market, but the pace of review has meant that many products remain in regulatory limbo years after the deadline.

The impact on market structure has been the PMTA's most significant and most controversial effect. The cost of preparing a single PMTA—estimated at $2–10 million per product—created a barrier to market entry that only well-capitalized companies could clear. The result has been a dramatic market consolidation: the thousands of small, independent e-liquid manufacturers that characterized the industry's early years have largely disappeared from the legal market, replaced by a handful of large companies (primarily tobacco-owned) with the resources to navigate the regulatory process. The PMTA process has accelerated the industry's transformation from a fragmented, entrepreneurial market to a concentrated, corporate one. Whether this consolidation serves public health—by eliminating the least professionalized, least quality-controlled manufacturers—or harms it—by reducing product variety and handing the market to tobacco companies—is the central debate about the PMTA's legacy.

The flavor question has been the PMTA's most contentious dimension. The FDA has authorized almost exclusively tobacco-flavored e-liquids, effectively eliminating flavored products from the legal market through regulatory action rather than legislation. The agency's position is that flavored products present higher youth-appeal risks that manufacturers have not adequately addressed in their applications. Critics argue that the FDA has imposed an impossible evidentiary standard—requiring manufacturers to demonstrate that flavored products benefit adult smokers enough to outweigh youth risks, while providing no guidance on what evidence would satisfy that standard. The result has been a de facto flavor ban implemented through regulatory process rather than democratic deliberation. The impact on adult vapers—many of whom report that flavors are essential to their smoking cessation—has been significant and largely unmeasured by the FDA's own post-market surveillance.

The enforcement dimension has been the PMTA's most visible failure. The FDA has authorized a small number of products and issued marketing denial orders for many more—but unauthorized products remain widely available. Disposable vapes from manufacturers who never submitted PMTAs, or whose applications were denied, continue to be imported, distributed, and sold through convenience stores, vape shops, and online retailers. The FDA's enforcement capacity—inspections, warning letters, seizures—has not matched the scale of the unauthorized market. The result is a regulatory regime that's strict on paper and porous in practice, with authorized products competing against unauthorized ones that are functionally identical but haven't cleared the regulatory process. The enforcement gap undermines the integrity of the PMTA system and disadvantages the companies that have invested in compliance.

The international dimension has been the PMTA's most unexpected consequence. Several countries have adopted or are considering PMTA-style premarket review for nicotine products—the UK's MHRA notification scheme, the EU's potential revision of the Tobacco Products Directive, and various LMIC regulatory frameworks influenced by the FDA model. The global diffusion of PMTA-style regulation creates a potential future where novel reduced-risk nicotine products must clear multiple expensive, duplicative regulatory reviews to reach global markets—raising the cost of innovation and limiting availability in LMICs that lack their own regulatory review capacity. The PMTA model, designed for the U.S. market, is becoming a global template—with consequences for nicotine product access worldwide that have not been adequately debated.

The PMTA process is a work in progress, not a finished system. The FDA is refining its review criteria, developing more efficient pathways for certain product categories, and attempting to address the enforcement gap. The long-term impact on population health—whether the PMTA process accelerates smoking cessation by ensuring product quality and restricting youth access, or slows it by reducing product variety and adult access—will not be known for years. What's clear is that the PMTA process has fundamentally restructured the U.S. nicotine market, and that the restructuring has implications far beyond the products the FDA has authorized or denied. The PMTA process is an experiment in pre-market regulation of an established consumer market—a regulatory model that's rare outside pharmaceuticals and that's being watched closely by every country considering how to regulate the rapidly evolving nicotine landscape.